article thumbnail

Shorter timelines, evolving strategies: Four key trends in regulatory approvals of new medicines

Clarivate

Increased collaboration between regulatory agencies also appears to be having a positive impact on the roll out of new drugs. The following blog post summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2012-2021. FDA continues to approve the most NASs.

article thumbnail

Treating Alzheimer’s: regulatory hurdles in an anti-amyloid revolution

European Pharmaceutical Review

The US Food and Drug Administration (FDA) recently converted the accelerated approval of the drug, granted in January 2023 , to a full authorisation on the back of data from pivotal clinical studies conducted by the marketing authorisation holder, Eisai 1. References Drugs@FDA: FDA-Approved Drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GAMP 5 update: computerized system expectations for pharma manufacturers

European Pharmaceutical Review

As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.” FDA, 2022. . About the authors.

article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. The research also identified other challenges for mRNA therapeutics’ delivery , including their high cost, susceptibility to degradation by ribonucleases and limitations with drug delivery systems.

article thumbnail

Cancer: Progress but a long way to go

World of DTC Marketing

The mortality rate from lung cancer has dropped in recent decades—by 56% in men from 1990 to 2019 and by 32% in women from 2002 to 2019. But it’s’ still the leading cause of cancer deaths. The Food and Drug Administration approved them, an analysis JAMA Internal Medicine found. sustaining life)?

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline.

article thumbnail

Cardiovascular Medical Device Sales With Marc Toth

Evolve Your Success

The foods are put on the trays, then go up to the person who has a diabetic diet. It’s the first drug-eluting heart stent in the world. It was April 23, 2002. Do you want to go into healthcare administration? Hospital administration jobs are going away because hospitals consolidate and try to cut costs.

Medical 52